Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:11:02.227Z.
Calculation as of: 2026-10-06T14:11:02.227Z.
Quote observation: 2026-10-06T14:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d16669f7a2c0e1646e6313a61118319ccaec2b3022f40527d46d929c834448
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$231.69M
EV/EBITDA Ratio
N/A
TTM Avg
133.55x
3Y Avg
183129.66x
5Y Avg
183129.66x
Market Cap
$236.90M
EV/EBITDA Ratio
N/A
TTM Avg
21.13x
3Y Avg
83.14x
5Y Avg
83.14x
Market Cap
$240.76M
EV/EBITDA Ratio
12.96x
TTM Avg
20.89x
3Y Avg
46.57x
5Y Avg
889.74x
Market Cap
$244.74M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$239.06M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$225.44M
EV/EBITDA Ratio
N/A
TTM Avg
1.40x
3Y Avg
1.40x
5Y Avg
1.40x
Market Cap
$243.66M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $234.93M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | N/A | 133.55x | 183129.66x | 183129.66x |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.90M | N/A | 21.13x | 83.14x | 83.14x |
| High Tide Inc. (HITI)vs › | $240.76M | 12.96x | 20.89x | 46.57x | 889.74x |
| Biodesix, Inc. (BDSX)vs › | $240.50M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.74M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $239.06M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $225.44M | N/A | 1.40x | 1.40x | 1.40x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 28.93x | 31.09x | 27.66x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
